English | Español

Abbvie
Press release submission | Jul 24, 2021

DALVANCE® (dalbavancin) Receives FDA Approval to Treat Acute Bacterial Skin and Skin Structure Infections in Pediatric Patients

Press release submission | Aug 15, 2020

ABBVIE: New England Journal of Medicine Publishes Positive Phase 3 Data of Venetoclax Combination in Acute Myeloid Leukemia (AML) Patients
Press release submission | Nov 26, 2018

ABBVIE: Receives US FDA Accelerated Approval for VENCLEXTA® (venetoclax) for Treatment of Newly-Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy
Press release submission | Oct 26, 2018

ABBVIE: To Assume Full Development and Commercial Control of Cystic Fibrosis Research Program
Press release submission | Sep 23, 2018

ABBVIE: Announces $5 Million Donation to Family Reach to Support Children Battling Cancer and Their Families
Carrie Bradon | Nov 28, 2017

AbbVie to take part in Evercore ISI Biopharma Catalyst conference
Kathy Adams | Nov 15, 2017

AbbVie executive to present at Jefferies London Healthcare Conference
Robert Hadley | Nov 7, 2017

FDA fast-tracking review for AbbVie’s endometriosis drug

Trending
+ Pharmaceuticals
Patient Daily | Jun 23, 2025

PhRMA says patients in the U.S. face higher prescription costs due to 340B program
+ Pharmaceuticals
Patient Daily | Jun 18, 2025

ENT specialist on acid reflux: ‘You actually have a structural issue that may predispose you to sinusitis’
+ Pharmaceuticals
Patient Daily | Jun 19, 2025

Patients Come First spokesperson on 340B reform: ‘Americans deserve a system that prioritizes patients first, not pharmacy middlemen’
+ Pharmaceuticals
Patient Daily | Jun 19, 2025

FDA loophole lets low-quality drugs from China and India flood U.S. market, while American manufacturers are held to higher standards